Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2014 and recent business highlights.
“We have made good progress advancing our lead product candidate, EBI-005, since the second quarter of this year. We are encouraged by the Phase 2 top-line safety and efficacy results for EBI-005 in patients with moderate to severe allergic conjunctivitis, as we believe these data further validate EBI-005 as a clinically active anti-inflammatory ocular agent,” said Abbie Celniker, PhD, President and Chief Executive Officer. “Additionally, we recently completed patient enrollment in our first pivotal Phase 3 study of EBI-005 in patients with dry eye disease and expect to report top-line results of that trial in the second quarter of 2015.”
Help employers find you! Check out all the jobs and post your resume.
